Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 418 articles:
HTML format



Single Articles


    July 2025
  1. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
    Gynecol Oncol. 2025;199:96-102.
    PubMed     Abstract available


    June 2025
  2. RANDALL L, Xiang Y, Matsumoto T, Giannarelli D, et al
    Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
    Gynecol Oncol. 2025;199:88-95.
    PubMed     Abstract available


  3. LINDEMANN K, Berton D, Sehouli J, Christensen RD, et al
    NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2025;199:79-87.
    PubMed     Abstract available


  4. DZYUBAK O, Glass K, Watts M, Tarafdar O, et al
    Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
    Gynecol Oncol. 2025;199:72-78.
    PubMed     Abstract available


  5. GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
    Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
    Gynecol Oncol. 2025;199:64-71.
    PubMed     Abstract available


  6. WANG M, Dong T, Lucero M, Pan W, et al
    Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
    Gynecol Oncol. 2025;199:57-63.
    PubMed     Abstract available


  7. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
    Optimizing therapy for cervical cancers - Translating trial data into clinical decision-making.
    Gynecol Oncol. 2025;199:47-50.
    PubMed    


  8. KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
    Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
    Gynecol Oncol. 2025;199:40-46.
    PubMed     Abstract available


  9. VARGIU V, Rosati A, Santullo F, Figa M, et al
    REACT bowel REcovery after CyToreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;199:32-39.
    PubMed     Abstract available


  10. LIU Y, Zhou Y, Zhou Z, Rao X, et al
    GTN misdiagnosed as ectopic pregnancy: a 17-year retrospective cohort study.
    Gynecol Oncol. 2025;199:27-31.
    PubMed     Abstract available


  11. WEI TY, Wu CC, Hsu YT, Lin WH, et al
    An exploratory analysis of driver gene alterations and their potential prognostic relevance in endometrial cancer with POLE exonuclease domain mutations.
    Gynecol Oncol. 2025;199:17-26.
    PubMed     Abstract available


  12. BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
    Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
    Gynecol Oncol. 2025;199:10-16.
    PubMed     Abstract available


  13. HUEPENBECKER SP, Iniesta MD, Munsell MF, Mandayam S, et al
    No increase in chronic kidney disease after postoperative acute kidney injury in gynecologic oncologic ERAS surgery.
    Gynecol Oncol. 2025;198:168-175.
    PubMed     Abstract available


  14. DAMIAN FB, De Melo AC, Dal Molin GZ, Nogueira-Rodrigues A, et al
    A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
    Gynecol Oncol. 2025;198:161-167.
    PubMed     Abstract available


  15. VINTZILEOS W, Beer H, Sunkara Y, Pruszynski J, et al
    Prognostic indicators of recurrence and treatment-free interval in uterine carcinosarcoma.
    Gynecol Oncol. 2025;198:154-160.
    PubMed     Abstract available


  16. BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
    Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
    Gynecol Oncol. 2025;198:130-136.
    PubMed     Abstract available


  17. MATSUO K, Friedman EL, Lee MW, Masjedi AD, et al
    Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission.
    Gynecol Oncol. 2025;198:146-153.
    PubMed     Abstract available


  18. NGUYEN JMV, Zigras T, Gayowsky A, Marcucci M, et al
    Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.
    Gynecol Oncol. 2025;198:137-145.
    PubMed     Abstract available


  19. FU Z, Borho L, Taylor SE, Kelemen LE, et al
    Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
    Gynecol Oncol. 2025;198:112-129.
    PubMed     Abstract available


  20. MELO V, Vanegas G, O'Riordan DL, Kuruvilla P, et al
    A population health approach to assessing for and addressing palliative care needs in outpatients with advanced gynecologic malignancies.
    Gynecol Oncol. 2025;198:104-111.
    PubMed     Abstract available


  21. INIESTA MD, Ramirez PT, Munsell MF, Basabe S, et al
    Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial.
    Gynecol Oncol. 2025;198:96-103.
    PubMed     Abstract available


  22. RING KL, Mills AM, Howitt BE, Grisham RN, et al
    Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
    Gynecol Oncol. 2025;197:57-65.
    PubMed     Abstract available


  23. KURNIT KC
    The search for new therapeutic options for uterine carcinosarcoma.
    Gynecol Oncol. 2025;197:A1-A2.
    PubMed    


    May 2025
  24. KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
    The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
    Gynecol Oncol. 2025;198:90-95.
    PubMed     Abstract available


  25. CHO WK, Park W, Kim SW, Lee KK, et al
    Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
    Gynecol Oncol. 2025;198:84-89.
    PubMed     Abstract available


  26. PHAM ENB, van den Berg CB, Kokke NCCJ, van Marion R, et al
    Molecular diversity in uterine carcinosarcoma: Beyond TP53.
    Gynecol Oncol. 2025;198:75-83.
    PubMed     Abstract available


  27. IIDA Y, Churchman M, Hollis RL, Taylor S, et al
    Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.
    Gynecol Oncol. 2025;198:66-74.
    PubMed     Abstract available


  28. LAM C, Zhou Q, Aghajanian C, Abu-Rustum NR, et al
    Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis.
    Gynecol Oncol. 2025;198:59-65.
    PubMed     Abstract available


  29. EHIMIAGHE E, Marjon N, Post MD, Corr BR, et al
    The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective.
    Gynecol Oncol. 2025;198:55-58.
    PubMed    


  30. ACOSTA U, Bebia V, Torne A, Carreras-Dieguez N, et al
    Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group.
    Gynecol Oncol. 2025;198:49-54.
    PubMed     Abstract available


  31. NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
    Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
    Gynecol Oncol. 2025;198:42-48.
    PubMed     Abstract available


  32. YANG W, Shen Y, Tian Y, Xiao X, et al
    Evaluation of mutations detected in uterine exfoliated cells as a diagnostic tool for endometrial cancer.
    Gynecol Oncol. 2025;198:33-41.
    PubMed     Abstract available


  33. LEE JY, Boonyapipat S, Yuan G, Kim HS, et al
    AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2025;198:25-32.
    PubMed     Abstract available


  34. GU J, Zheng W, Li F, Luo C, et al
    Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC.
    Gynecol Oncol. 2025;198:17-24.
    PubMed     Abstract available


  35. BERG HF, Trovik J, Hjelmeland ME, Lien HE, et al
    Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining.
    Gynecol Oncol. 2025;198:9-16.
    PubMed     Abstract available


  36. LEE EK, Xiong N, Krasner C, Polak M, et al
    Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
    Gynecol Oncol. 2025;198:1-8.
    PubMed     Abstract available


  37. WAGAR MK, Reetz E, Huang D, Kao MJ, et al
    Patterns of primary metastasis and recurrence in mismatch repair deficiency and p53 abnormal endometrial carcinoma.
    Gynecol Oncol. 2025;197:171-178.
    PubMed     Abstract available


  38. WAGGONER RM, Mahoney RP, Nathan D, Zell JA, et al
    Assessing preventive gynecologic decisions in individuals with Lynch syndrome.
    Gynecol Oncol. 2025;197:163-170.
    PubMed     Abstract available


  39. BYRNE ME, Selenica P, Dessources K, Da Cruz Paula A, et al
    Peritoneal washings analysis in endometrial cancer: Comparison of somatic mutation detection with panel sequencing and traditional cytology.
    Gynecol Oncol. 2025;197:155-162.
    PubMed     Abstract available


  40. XIAO Y, Pang J, Zhou Y, Lu J, et al
    FRalpha expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates.
    Gynecol Oncol. 2025;197:146-154.
    PubMed     Abstract available


  41. EVANS E, Dholakia J, Abraham J, Hinton A, et al
    Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
    Gynecol Oncol. 2025;197:139-145.
    PubMed     Abstract available


  42. MOUFARRIJ S, Dopeso H, Brown DN, Green H, et al
    TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
    Gynecol Oncol. 2025;197:129-138.
    PubMed     Abstract available


  43. KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
    Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
    Gynecol Oncol. 2025;197:121-128.
    PubMed     Abstract available


  44. KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
    Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
    Gynecol Oncol. 2025;197:116-120.
    PubMed     Abstract available


  45. ETTORRE VM, Bellone S, Greenman M, McNamara B, et al
    A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
    Gynecol Oncol. 2025;197:110-115.
    PubMed     Abstract available


  46. SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
    Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
    Gynecol Oncol. 2025;197:102-109.
    PubMed     Abstract available


  47. THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
    OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
    PubMed     Abstract available


  48. ALIMENA S, Reid H, Bercow A, Feltmate C, et al
    Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018.
    Gynecol Oncol. 2025;196:175-181.
    PubMed     Abstract available


  49. CORNEL KMC, Mehta MP, Swift BE, Covens A, et al
    The use of indocyanine green (ICG) for sentinel lymph node detection in vulvar cancer.
    Gynecol Oncol. 2025;196:146-151.
    PubMed     Abstract available


  50. STUEBS FA, Knoll A, Hartmann A, Matek C, et al
    Trop2-expression in primary vulvar squamous cell carcinoma.
    Gynecol Oncol. 2025;196:78-84.
    PubMed     Abstract available


    April 2025
  51. LOUKOVAARA M, Pasanen A, Butzow R
    Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2025;197:96-101.
    PubMed     Abstract available


  52. BAE J, Kim U, Paik ES, Lim MC, et al
    Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.
    Gynecol Oncol. 2025;197:91-95.
    PubMed     Abstract available


  53. JOHNSON CR, Aryasomayajula C, Francoeur AA, Stewart C, et al
    Pathogenic germline variants among women with uterine cancer by ancestry: A commercial laboratory collaborative research registry study.
    Gynecol Oncol. 2025;197:83-90.
    PubMed     Abstract available


  54. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
    Gynecol Oncol. 2025;197:74-82.
    PubMed     Abstract available


  55. YOU B, Anderson C, Cecere SC, Carrot A, et al
    Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
    Gynecol Oncol. 2025;197:66-73.
    PubMed     Abstract available


  56. FITZGERALD KJ, Konstantinopoulos P, Matulonis U, Liu J, et al
    A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
    Gynecol Oncol. 2025;197:51-56.
    PubMed     Abstract available


  57. LEON-CASTILLO A, Horeweg N, Peters EEM, Ter Haar N, et al
    Pattern of recurrence of the molecular subgroups in stage I high-grade endometrial cancer.
    Gynecol Oncol. 2025;197:43-50.
    PubMed     Abstract available


  58. XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
    Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
    Gynecol Oncol. 2025;197:34-42.
    PubMed     Abstract available


  59. FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al
    Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery.
    Gynecol Oncol. 2025;196:182-191.
    PubMed     Abstract available


  60. GRCEVICH L, Chuzhyk O, Giannini A, McGree ME, et al
    Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer.
    Gynecol Oncol. 2025;197:19-24.
    PubMed     Abstract available


  61. WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
    Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;197:11-18.
    PubMed     Abstract available


  62. RIOS-DORIA E, Parker EU, Kohrn BF, Pike M, et al
    TP53 somatic evolution in the normal endometrium of Black and White individuals.
    Gynecol Oncol. 2025;197:1-10.
    PubMed     Abstract available


  63. MORRIS DH, Kosmacki A, Tolby L, Marx C, et al
    Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.
    Gynecol Oncol. 2025;196:168-174.
    PubMed     Abstract available


  64. BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al
    Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study.
    Gynecol Oncol. 2025;196:160-167.
    PubMed     Abstract available


  65. RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
    Hysterectomy or not for borderline ovarian tumor in menopause?
    Gynecol Oncol. 2025;196:152-159.
    PubMed     Abstract available


  66. ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
    The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
    Gynecol Oncol. 2025;196:137-145.
    PubMed     Abstract available


  67. METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
    Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
    Gynecol Oncol. 2025;196:129-136.
    PubMed     Abstract available


  68. HABLASE R, Steinke J, Aslam A, Jose R, et al
    Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
    Gynecol Oncol. 2025;196:121-128.
    PubMed     Abstract available


  69. GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
    ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
    Gynecol Oncol. 2025;196:113-120.
    PubMed     Abstract available


  70. COSGROVE CM, Suarez AA, Haight PJ, Villacres A, et al
    Exploring endometrial cancer risk stratification by copy number assessment.
    Gynecol Oncol. 2025;196:99-106.
    PubMed     Abstract available


  71. KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
    Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2025;196:107-112.
    PubMed     Abstract available


  72. VARGIU V, Santullo F, Scambia G, Naldini A, et al
    STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
    Gynecol Oncol. 2025;196:92-98.
    PubMed     Abstract available


  73. BUJNAK AC, Greenberg D, Chang J, Tseng J, et al
    Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes.
    Gynecol Oncol. 2025;196:85-91.
    PubMed     Abstract available


  74. WOLF B, Trantaki DS, Horn LC, Aktas B, et al
    Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.
    Gynecol Oncol. 2025;196:69-77.
    PubMed     Abstract available


  75. WESTRICK AC, Bailey Z, Schlumbrecht M
    Influence of residential segregation and health provider density on advanced stage endometrial cancer diagnoses.
    Gynecol Oncol. 2025;196:62-68.
    PubMed     Abstract available


  76. HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
    MUTYH: Possibly another important gene in ovarian cancer?
    Gynecol Oncol. 2025;196:59-61.
    PubMed    


  77. CIOFFI R, Fruscio R, Sabetta G, Bergamini A, et al
    Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: A MITO-9 retrospective study.
    Gynecol Oncol. 2025;196:54-58.
    PubMed     Abstract available


  78. CHAM S, Kumar A, Walter LC, Lichtman S, et al
    Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer.
    Gynecol Oncol. 2025;196:42-53.
    PubMed     Abstract available


  79. TA QD, Do C, Sharma K, Sorooshian HZ, et al
    Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
    Gynecol Oncol. 2025;196:36-41.
    PubMed     Abstract available


  80. LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al
    Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
    Gynecol Oncol. 2025;195:122-133.
    PubMed     Abstract available


  81. BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
    Signal transduction pathway activity in adult-type granulosa cell tumor samples.
    Gynecol Oncol. 2025;195:6-11.
    PubMed     Abstract available


  82. PODDER V, Slomovitz BM
    Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity.
    Gynecol Oncol. 2025;195:A1-A2.
    PubMed    


    March 2025
  83. LORUSSO D, Oaknin A, Borges GS, Damian F, et al
    Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2025;196:28-35.
    PubMed     Abstract available


  84. XIE H, Sun L, Yao S, Tian X, et al
    Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.
    Gynecol Oncol. 2025;196:16-27.
    PubMed     Abstract available


  85. KIM J, Jang J, Lim MC, Kim MH, et al
    Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
    Gynecol Oncol. 2025;196:10-15.
    PubMed     Abstract available


  86. MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
    ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
    Gynecol Oncol. 2025;195:192-199.
    PubMed     Abstract available


  87. BUJNAK AC, Solaru SA, Tewari K
    Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
    Gynecol Oncol. 2025;195:180-191.
    PubMed     Abstract available


  88. ETHIER JL, Shephard C, Granados DP, Dutta N, et al
    Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
    Gynecol Oncol. 2025;196:1-9.
    PubMed     Abstract available


  89. JOHANNET P, Flint M, Chui MH, Konner J, et al
    Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
    Gynecol Oncol. 2025;195:173-179.
    PubMed     Abstract available


  90. LI Y, Wu M, Liu Q, Huang C, et al
    Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
    Gynecol Oncol. 2025;195:165-172.
    PubMed     Abstract available


  91. LEE EK, Kolin DL, Matulonis UA, Erickson BK, et al
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.
    Gynecol Oncol. 2025;195:152-164.
    PubMed     Abstract available


  92. DEMARI JA, Glassman D, Smith S, Darby JP, et al
    Endometrial cancer somatic testing practice patterns among gynecologic oncologists.
    Gynecol Oncol. 2025;195:149-151.
    PubMed    


  93. SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
    Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
    Gynecol Oncol. 2025;195:144-148.
    PubMed     Abstract available


  94. DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
    Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
    Gynecol Oncol. 2025;195:134-143.
    PubMed     Abstract available


  95. CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
    Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
    Gynecol Oncol. 2025;195:106-114.
    PubMed     Abstract available


  96. SALINARO J, Singh K, Sands N, Gill V, et al
    Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
    Gynecol Oncol. 2025;195:115-121.
    PubMed     Abstract available


  97. ENGH A, Rueegg CS, Bjerre Trent PK, Opheim LO, et al
    Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study.
    Gynecol Oncol. 2025;195:82-88.
    PubMed     Abstract available


  98. LINDEMANN K, Siegenthaler F, Lande KT, Casas-Arozamena C, et al
    Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.
    Gynecol Oncol. 2025;195:98-105.
    PubMed     Abstract available


  99. ZAMMARRELLI WA 3RD, Nandakumar S, Kertowidjojo E, Nguyen B, et al
    The genomic landscape of distant metastatic endometrial cancer.
    Gynecol Oncol. 2025;195:89-97.
    PubMed     Abstract available


  100. TYAN K, Liu KX, Smart AC, Feltmate CM, et al
    Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
    Gynecol Oncol. 2025;195:75-81.
    PubMed     Abstract available


  101. CARTER J, Huang HQ, Monk BJ, Kim YB, et al
    Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
    Gynecol Oncol. 2025;195:50-58.
    PubMed     Abstract available


  102. BAE-JUMP VL, Sill MW, Gehrig PA, Merker JD, et al
    A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2025;195:66-74.
    PubMed     Abstract available


  103. COVENS A, Huang HQ, Monk BJ, Kim YB, et al
    Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
    Gynecol Oncol. 2025;195:59-65.
    PubMed     Abstract available


  104. LA TORRE F, Hurni Y, Farsi E, Nardi E, et al
    Adenomyosis associated with endometrial cancer: Possible correlation with pathological, immunohistochemical and molecular characteristics.
    Gynecol Oncol. 2025;195:45-49.
    PubMed     Abstract available


  105. LI X, Wang Z, Man X, Dai X, et al
    Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
    Gynecol Oncol. 2025;195:34-44.
    PubMed     Abstract available


  106. HICKS A, Borho L, Elishaev E, Berger J, et al
    All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
    Gynecol Oncol. 2025;195:26-33.
    PubMed     Abstract available


  107. MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
    Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
    Gynecol Oncol. 2025;195:16-25.
    PubMed     Abstract available


  108. FUCA G, Dell'Acqua C, Peruffo B, Lalli G, et al
    WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy.
    Gynecol Oncol. 2025;195:12-15.
    PubMed    


  109. DINKINS KG, Lee GM, Arend RC, Leath CA 3rd, et al
    Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024.
    Gynecol Oncol. 2025;194:153-158.
    PubMed     Abstract available


  110. HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
    An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
    Gynecol Oncol. 2025;194:145-152.
    PubMed     Abstract available


  111. WENZEL L, McKinney C, Jensen S, Peipert D, et al
    Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).
    Gynecol Oncol. 2025;194:137-144.
    PubMed     Abstract available


  112. VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al
    Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok.
    Gynecol Oncol. 2025;194:131-136.
    PubMed     Abstract available


  113. LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
    An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
    Gynecol Oncol. 2025;194:125-130.
    PubMed     Abstract available


  114. DEBBICHE I, Wang CC, Gomez-Roas M, Foley OW, et al
    Rest assured: High sleep efficiency reduces postoperative complications and opioid prescriptions in patients undergoing surgeries with gynecologic oncologists.
    Gynecol Oncol. 2025;194:119-124.
    PubMed     Abstract available


  115. VAN VELZEN AF, Tulling AJ, van Poelgeest MIE, Bosse T, et al
    Predicting lymph node metastases in three different vulvar squamous cell carcinoma subgroups.
    Gynecol Oncol. 2025;194:86-90.
    PubMed     Abstract available


  116. ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
    Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
    Gynecol Oncol. 2025;194:1-10.
    PubMed     Abstract available


  117. ESKANDER RN
    Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?
    Gynecol Oncol. 2025;194:A3-A4.
    PubMed    


    February 2025
  118. WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al
    Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2025;195:1-5.
    PubMed     Abstract available


  119. ASARE A, Previs RA, Spinosa D, Fellman B, et al
    Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
    Gynecol Oncol. 2025;194:112-118.
    PubMed     Abstract available


  120. HAIGHT PJ, Sanchez M, Thomas SM, Smitherman C, et al
    Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
    Gynecol Oncol. 2025;194:98-104.
    PubMed     Abstract available


  121. NOLIN AC, Atkins SL, Myers ER, Wentzensen N, et al
    Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals.
    Gynecol Oncol. 2025;194:105-111.
    PubMed     Abstract available


  122. MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al
    Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
    Gynecol Oncol. 2025;194:91-97.
    PubMed     Abstract available


  123. HAIGHT P, Bilbe C, Riedinger C, Backes F, et al
    Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
    Gynecol Oncol. 2025;194:80-85.
    PubMed     Abstract available


  124. ALVERO AB, Wu S, Farrell A, Kim S, et al
    Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
    Gynecol Oncol. 2025;194:71-79.
    PubMed     Abstract available


  125. SUN H, Huo X, Bi X, Cao D, et al
    Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
    Gynecol Oncol. 2025;194:60-70.
    PubMed     Abstract available


  126. MATSUO K, Agarwal J, Chen L, Furey KB, et al
    Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
    Gynecol Oncol. 2025;194:51-59.
    PubMed     Abstract available


  127. TUBRIDY EA, Campbell A, Mulugeta-Gordon L, Andriani L, et al
    Impact of telehealth legislation on gynecologic oncology services: Policy updates.
    Gynecol Oncol. 2025;194:48-50.
    PubMed    


  128. GAILLARD S, Verma N, Berg M, Harrison J, et al
    A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2025;194:41-47.
    PubMed     Abstract available


  129. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
    Gynecol Oncol. 2025;194:33-40.
    PubMed     Abstract available


  130. KIM J, Park SY, Kim JH, Lee SW, et al
    Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
    Gynecol Oncol. 2025;194:25-32.
    PubMed     Abstract available


  131. ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
    Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
    Gynecol Oncol. 2025;194:18-24.
    PubMed     Abstract available


  132. VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
    Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
    Gynecol Oncol. 2025;194:11-17.
    PubMed     Abstract available


  133. CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
    High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
    Gynecol Oncol. 2025;193:148-155.
    PubMed     Abstract available


  134. STUEBS FA, Knoll A, Hartmann A, Leikauf LS, et al
    PD-L1-Expression in primary and recurrent vulvar squamous cell cancer.
    Gynecol Oncol. 2025;193:98-104.
    PubMed     Abstract available


  135. HOROWITZ NS, St Laurent JD, Berkowitz RS
    Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances?
    Gynecol Oncol. 2025;193:A1-A2.
    PubMed    


    January 2025
  136. MAKI PM, Rubin LH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2025;193:141-147.
    PubMed     Abstract available


  137. KIM YJ, Lee J, Park S, Kim YM, et al
    The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2025;193:136-140.
    PubMed     Abstract available


  138. CLEMENTS A, Enserro D, Strickland KC, Previs R, et al
    Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
    Gynecol Oncol. 2025;193:119-129.
    PubMed     Abstract available


  139. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
    Gynecol Oncol. 2025;193:130-135.
    PubMed     Abstract available


  140. TOBONI MD, Dinkins K, Wu S, Mattox T, et al
    Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
    Gynecol Oncol. 2025;193:89-97.
    PubMed     Abstract available


  141. SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
    Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
    Gynecol Oncol. 2025;193:113-118.
    PubMed     Abstract available


  142. UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al
    Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
    Gynecol Oncol. 2025;193:105-112.
    PubMed     Abstract available


  143. DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al
    Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
    Gynecol Oncol. 2025;193:81-88.
    PubMed     Abstract available


  144. WANG H, Zhu J, Zou D, Rao Q, et al
    Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
    Gynecol Oncol. 2025;193:58-64.
    PubMed     Abstract available


  145. AHMED J, Stephen B, Khawaja MR, Yang Y, et al
    A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2025;193:73-80.
    PubMed     Abstract available


  146. MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
    Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
    Gynecol Oncol. 2025;193:65-72.
    PubMed     Abstract available


  147. LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
    Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
    Gynecol Oncol. 2025;193:41-48.
    PubMed     Abstract available


  148. RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
    Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:49-57.
    PubMed     Abstract available


  149. BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
    Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:30-40.
    PubMed     Abstract available


  150. WALKER AR, Leite S, Taylor N, Graul A, et al
    Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
    Gynecol Oncol. 2025;193:24-29.
    PubMed     Abstract available


  151. SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al
    Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups.
    Gynecol Oncol. 2025;193:12-19.
    PubMed     Abstract available


  152. VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al
    Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.
    Gynecol Oncol. 2025;192:163-170.
    PubMed     Abstract available


  153. MARINO G, Marchetta L, Negri S, Testa F, et al
    Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
    Gynecol Oncol. 2025;192:89-93.
    PubMed     Abstract available


    December 2024
  154. NEILSON A, Jamieson A, Chiu D, Leung S, et al
    Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
    Gynecol Oncol. 2024;193:1-11.
    PubMed     Abstract available


  155. MADDY BP, Tischer KM, McGree ME, Fought AJ, et al
    Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience.
    Gynecol Oncol. 2024;192:181-188.
    PubMed     Abstract available


  156. VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al
    Less is more: The benefits of reduced follow-up in gynecologic cancers.
    Gynecol Oncol. 2024;192:178-180.
    PubMed    


  157. LIU YL, Praiss AM, Chiang S, Devereaux K, et al
    Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
    Gynecol Oncol. 2024;192:171-177.
    PubMed     Abstract available


  158. KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
    Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
    Gynecol Oncol. 2024;192:155-162.
    PubMed     Abstract available


  159. AZAIS H, Brochard C, Taly V, Benoit L, et al
    Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
    Gynecol Oncol. 2024;192:145-154.
    PubMed     Abstract available


  160. NGUYEN T, Yi Y, Morron S, Brittain D, et al
    Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
    Gynecol Oncol. 2024;192:137-144.
    PubMed     Abstract available


  161. MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
    Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
    Gynecol Oncol. 2024;192:128-136.
    PubMed     Abstract available


  162. GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
    Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
    Gynecol Oncol. 2024;192:120-127.
    PubMed     Abstract available


  163. CASTELLANO T, Lara OD, McCormick C, Chase D, et al
    Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices.
    Gynecol Oncol. 2024;192:111-119.
    PubMed     Abstract available


  164. PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
    Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecol Oncol. 2024;192:102-110.
    PubMed     Abstract available


  165. COLSON-FEARON D, Viswanathan AN
    Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021.
    Gynecol Oncol. 2024;191:228-232.
    PubMed     Abstract available


  166. MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al
    Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations.
    Gynecol Oncol. 2024;191:212-218.
    PubMed     Abstract available


  167. FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al
    Surgery after upfront chemoradiation in locally advanced squamous cell vulvar cancer: Analysis of postoperative outcomes and survival.
    Gynecol Oncol. 2024;191:106-113.
    PubMed     Abstract available


  168. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
    Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
    Gynecol Oncol. 2024;191:100-105.
    PubMed     Abstract available


  169. THAYER EG, Manning-Geist BL
    Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:A1-A2.
    PubMed    


    November 2024
  170. SHU T, Liang Y, Zhang S, Sun T, et al
    The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
    Gynecol Oncol. 2024;192:94-101.
    PubMed     Abstract available


  171. BORHO L, Elishaev E, Bao R, O'Brien E, et al
    Association of neighborhood social vulnerability with ovarian cancer survival.
    Gynecol Oncol. 2024;192:32-39.
    PubMed     Abstract available


  172. KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
    Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
    Gynecol Oncol. 2024;192:80-88.
    PubMed     Abstract available


  173. CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
    A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
    Gynecol Oncol. 2024;192:73-79.
    PubMed     Abstract available


  174. SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
    Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
    Gynecol Oncol. 2024;192:65-72.
    PubMed     Abstract available


  175. KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
    Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
    Gynecol Oncol. 2024;192:59-64.
    PubMed     Abstract available


  176. MULUGETA-GORDON L, Smith AJB
    Insurance coverage and access to gynecologic oncology: Where are we are now.
    Gynecol Oncol. 2024;192:56-58.
    PubMed     Abstract available


  177. FRANCIS KE, Simon S, Gebski V, Joly F, et al
    Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
    Gynecol Oncol. 2024;192:50-55.
    PubMed     Abstract available


  178. POWELL MA, Cibula D, O'Malley DM, Boere I, et al
    Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Gynecol Oncol. 2024;192:40-49.
    PubMed     Abstract available


  179. COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
    Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
    Gynecol Oncol. 2024;192:24-31.
    PubMed     Abstract available


  180. DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
    Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
    Gynecol Oncol. 2024;191:275-286.
    PubMed     Abstract available


  181. VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
    Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
    Gynecol Oncol. 2024;192:15-23.
    PubMed     Abstract available


  182. MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
    Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
    Gynecol Oncol. 2024;192:8-14.
    PubMed     Abstract available


  183. HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
    What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
    Gynecol Oncol. 2024;192:1-7.
    PubMed     Abstract available


  184. KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
    KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
    Gynecol Oncol. 2024;191:299-306.
    PubMed     Abstract available


  185. LEE AW, Poynor V, Siddiqui S
    Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
    Gynecol Oncol. 2024;191:292-298.
    PubMed     Abstract available


  186. BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
    Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
    Gynecol Oncol. 2024;191:287-291.
    PubMed     Abstract available


  187. JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
    Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
    Gynecol Oncol. 2024;190:272-282.
    PubMed     Abstract available


  188. PROPPE L, Jaeger A, Goy Y, Petersen C, et al
    Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
    Gynecol Oncol. 2024;190:264-271.
    PubMed     Abstract available


  189. CHOI YK, Lee JH, Kim YS, Wee CW, et al
    Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
    Gynecol Oncol. 2024;190:222-229.
    PubMed     Abstract available


  190. SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
    Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
    Gynecol Oncol. 2024;190:189-199.
    PubMed     Abstract available


  191. NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
    Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
    Gynecol Oncol. 2024;190:160-166.
    PubMed     Abstract available


  192. HEUS C, Stelten S, Kenter GG, Buffart LM, et al
    Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
    Gynecol Oncol. 2024;190:131-138.
    PubMed     Abstract available


  193. WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
    Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
    Gynecol Oncol. 2024;190:124-130.
    PubMed     Abstract available


  194. METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
    Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
    Gynecol Oncol. 2024;190:62-69.
    PubMed     Abstract available


  195. MERTEN R, Strnad V, Karius A, Lotter M, et al
    Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
    Gynecol Oncol. 2024;190:35-41.
    PubMed     Abstract available


  196. TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
    Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
    Gynecol Oncol. 2024;190:18-27.
    PubMed     Abstract available


  197. BROWN J
    Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
    Gynecol Oncol. 2024;190:A1-A2.
    PubMed    


    October 2024
  198. VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
    Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
    Gynecol Oncol. 2024;191:265-274.
    PubMed     Abstract available


  199. HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
    Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:259-264.
    PubMed     Abstract available


  200. MOORE KN, Lorusso D, Oaknin A, Oza A, et al
    Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
    Gynecol Oncol. 2024;191:249-258.
    PubMed     Abstract available


  201. PENG S, Zheng Y, Liu J, Chen S, et al
    Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
    Gynecol Oncol. 2024;191:240-248.
    PubMed     Abstract available


  202. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
    Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
    Gynecol Oncol. 2024;191:233-239.
    PubMed     Abstract available


  203. NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
    Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:219-227.
    PubMed     Abstract available


  204. LI G, Li X, Yin R, Feng M, et al
    Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
    Gynecol Oncol. 2024;191:165-171.
    PubMed     Abstract available


  205. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
    Gynecol Oncol. 2024;191:201-211.
    PubMed     Abstract available


  206. HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
    Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
    Gynecol Oncol. 2024;191:194-200.
    PubMed     Abstract available


  207. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
    Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
    Gynecol Oncol. 2024;191:172-181.
    PubMed     Abstract available


  208. ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
    ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
    Gynecol Oncol. 2024;191:182-193.
    PubMed     Abstract available


  209. PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
    Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
    Gynecol Oncol. 2024;191:158-164.
    PubMed     Abstract available


  210. PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
    Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
    Gynecol Oncol. 2024;191:150-157.
    PubMed     Abstract available


  211. OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
    Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
    Gynecol Oncol. 2024;191:124-131.
    PubMed     Abstract available


  212. SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
    Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
    Gynecol Oncol. 2024;191:143-149.
    PubMed     Abstract available


  213. PINTO P, Moro F, Alcazar JL, Alessi S, et al
    Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
    Gynecol Oncol. 2024;191:132-142.
    PubMed     Abstract available


  214. KONG W, Deng B, Shen X, John C, et al
    Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
    Gynecol Oncol. 2024;191:116-123.
    PubMed     Abstract available


  215. NG ZY, Manchanda R, Lopez A, Obermair A, et al
    The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
    Gynecol Oncol. 2024;191:95-99.
    PubMed     Abstract available


  216. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
    Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
    Gynecol Oncol. 2024;191:86-94.
    PubMed     Abstract available


  217. RUSHTON T, Krause HB, Samec T, Elliott A, et al
    Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:80-85.
    PubMed     Abstract available


  218. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
    Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
    Gynecol Oncol. 2024;191:74-79.
    PubMed     Abstract available


  219. BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
    Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
    Gynecol Oncol. 2024;191:67-73.
    PubMed     Abstract available


  220. VAZ J, Piver R, Brzezinska B, Suhner J, et al
    Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
    Gynecol Oncol. 2024;189:129-136.
    PubMed     Abstract available


    September 2024
  221. WAN S, Gao Y, Wu S, Wang H, et al
    Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
    Gynecol Oncol. 2024;191:56-66.
    PubMed     Abstract available


  222. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
    Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
    Gynecol Oncol. 2024;191:45-55.
    PubMed     Abstract available


  223. PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
    Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
    Gynecol Oncol. 2024;191:37-44.
    PubMed     Abstract available


  224. YANG X, Li C, Li Z, Du D, et al
    The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
    Gynecol Oncol. 2024;191:31-36.
    PubMed     Abstract available


  225. LI X, Argenta PA, Brown K, Honeyfield K, et al
    Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
    Gynecol Oncol. 2024;191:25-30.
    PubMed     Abstract available


  226. JANG EB, Lee AJ, So KA, Lee SJ, et al
    Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
    Gynecol Oncol. 2024;191:19-24.
    PubMed     Abstract available


  227. ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
    Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:10-18.
    PubMed     Abstract available


  228. NIEF CA, Long SE, McCleary TL, Kidd E, et al
    Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
    Gynecol Oncol. 2024;190:298-306.
    PubMed     Abstract available


  229. MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
    Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Gynecol Oncol. 2024;191:1-9.
    PubMed     Abstract available


  230. FULLERTON R, Martell K, Khanolkar R, Phan T, et al
    Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
    Gynecol Oncol. 2024;190:291-297.
    PubMed     Abstract available


  231. BROWN J, Miller A, Holman LL, Backes F, et al
    Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
    Gynecol Oncol. 2024;190:283-290.
    PubMed     Abstract available


  232. NAHSHON C, Leitao MM Jr, Segev Y
    Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
    Gynecol Oncol. 2024;190:262-263.
    PubMed    


  233. ADJEI NN, Haas A, Zhao H, Primm KM, et al
    Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
    Gynecol Oncol. 2024;190:255-261.
    PubMed     Abstract available


  234. NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
    Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
    Gynecol Oncol. 2024;190:243-249.
    PubMed     Abstract available


  235. RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
    Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2024;190:236-242.
    PubMed     Abstract available


  236. MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
    Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2024;190:230-235.
    PubMed     Abstract available


  237. YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
    Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
    Gynecol Oncol. 2024;190:215-221.
    PubMed     Abstract available


  238. POTHURI B, Sawaged Z, Karpel HC, Li X, et al
    A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
    Gynecol Oncol. 2024;190:209-214.
    PubMed     Abstract available


  239. PIFER PM, Kilar CR, Beriwal S
    Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
    Gynecol Oncol. 2024;188:A1-A3.
    PubMed    


  240. WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
    Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
    Gynecol Oncol. 2024;188:125-130.
    PubMed     Abstract available


  241. WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
    A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
    Gynecol Oncol. 2024;188:120-124.
    PubMed     Abstract available


  242. MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
    Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
    Gynecol Oncol. 2024;188:81-82.
    PubMed    


  243. LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
    Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;188:71-80.
    PubMed     Abstract available


  244. WILHITE AM, Wu S, Xiu J, Gibney GT, et al
    A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
    Gynecol Oncol. 2024;188:13-21.
    PubMed     Abstract available


  245. POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
    Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
    Gynecol Oncol. 2024;188:1-7.
    PubMed     Abstract available


    August 2024
  246. LIM H, Kim SI, Kim MK, Yoon SH, et al
    Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
    Gynecol Oncol. 2024;190:200-208.
    PubMed     Abstract available


  247. MILLER EA, Chowdhary B, Chapman-Davis E
    Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
    Gynecol Oncol. 2024;190:186-188.
    PubMed     Abstract available


  248. MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
    Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
    Gynecol Oncol. 2024;190:146-152.
    PubMed     Abstract available


  249. FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
    Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
    Gynecol Oncol. 2024;190:179-185.
    PubMed     Abstract available


  250. QI C, Lyu M, Yao Z, Zhang F, et al
    SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
    Gynecol Oncol. 2024;190:167-178.
    PubMed     Abstract available


  251. CHUK E, Conway JL, Hanuschak J, Han K, et al
    Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
    Gynecol Oncol. 2024;190:153-159.
    PubMed     Abstract available


  252. KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
    Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
    Gynecol Oncol. 2024;190:139-145.
    PubMed     Abstract available


  253. BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
    The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
    Gynecol Oncol. 2024;190:119-123.
    PubMed     Abstract available


  254. YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
    Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
    Gynecol Oncol. 2024;190:113-118.
    PubMed     Abstract available


  255. SKOF E, Stegel V, Dragos VS, Blatnik A, et al
    Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
    Gynecol Oncol. 2024;190:104-112.
    PubMed     Abstract available


  256. LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
    Quality of life and survivorship in patients with low-grade ovarian cancer.
    Gynecol Oncol. 2024;190:96-103.
    PubMed     Abstract available


  257. KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
    Incidence of endometrial cancer in BRCA mutation carriers.
    Gynecol Oncol. 2024;189:148-155.
    PubMed     Abstract available


  258. WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
    Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
    Gynecol Oncol. 2024;190:90-95.
    PubMed     Abstract available


  259. GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
    The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
    Gynecol Oncol. 2024;190:84-89.
    PubMed     Abstract available


  260. SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
    Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
    Gynecol Oncol. 2024;190:78-83.
    PubMed     Abstract available


  261. GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
    Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
    Gynecol Oncol. 2024;190:70-77.
    PubMed     Abstract available


  262. ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
    Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
    Gynecol Oncol. 2024;190:53-61.
    PubMed     Abstract available


  263. YOKOI A, Machida H, Shimada M, Mastuo K, et al
    Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;190:42-52.
    PubMed     Abstract available


  264. GU Y, Liu Y, Cheng H, Wang W, et al
    Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
    Gynecol Oncol. 2024;190:28-34.
    PubMed     Abstract available


  265. CUN HT, Bernard L, Lande KT, Lawson BC, et al
    Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
    Gynecol Oncol. 2024;189:138-145.
    PubMed     Abstract available


  266. FROEDING LP, Jensen PT
    Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
    Gynecol Oncol. 2024;189:137.
    PubMed    


  267. OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
    Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
    Gynecol Oncol. 2024;190:11-17.
    PubMed     Abstract available


  268. RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
    Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
    Gynecol Oncol. 2024;190:1-10.
    PubMed     Abstract available


  269. HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
    Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
    Gynecol Oncol. 2024;189:125-128.
    PubMed     Abstract available


  270. CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
    Implementation of a financial navigation program in gynecologic oncology.
    Gynecol Oncol. 2024;189:119-124.
    PubMed     Abstract available


  271. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
    Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
    Gynecol Oncol. 2024;189:111-118.
    PubMed     Abstract available


  272. GLASER S, Han E
    Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
    Gynecol Oncol. 2024;187:A1-A2.
    PubMed    


  273. STROOT IAS, Bart J, Hollema H, Jalving M, et al
    Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
    Gynecol Oncol. 2024;187:198-203.
    PubMed     Abstract available


  274. WAGAR MK, Naik A, Zhang RC, Godecker A, et al
    Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
    Gynecol Oncol. 2024;187:192-197.
    PubMed     Abstract available


  275. DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
    Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
    Gynecol Oncol. 2024;187:145-150.
    PubMed     Abstract available


  276. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
    Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2024;187:113-119.
    PubMed     Abstract available


  277. ADOLPH L, Mann A, Liu XQ, Roberts L, et al
    Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
    Gynecol Oncol. 2024;187:74-79.
    PubMed     Abstract available


  278. VUE NC, Sassani J, Prairie B, Yin Y, et al
    Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
    Gynecol Oncol. 2024;187:58-63.
    PubMed     Abstract available


  279. SWIFT BE, Khoja L, Matthews J, Croke J, et al
    Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2024;187:46-50.
    PubMed     Abstract available


    July 2024
  280. DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
    Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
    Gynecol Oncol. 2024;189:109-110.
    PubMed    


  281. JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
    Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
    Gynecol Oncol. 2024;189:101-108.
    PubMed     Abstract available


  282. ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
    Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
    Gynecol Oncol. 2024;189:98-100.
    PubMed    


  283. GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
    Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gynecol Oncol. 2024;189:90-97.
    PubMed     Abstract available


  284. SULLIVAN MW, Kanbergs AN, Growdon WB
    Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
    Gynecol Oncol. 2024;189:88-89.
    PubMed    


  285. HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
    Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
    Gynecol Oncol. 2024;189:80-87.
    PubMed     Abstract available


  286. FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
    ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;189:75-79.
    PubMed     Abstract available


  287. LEE YW, Wang V, Wang MJ, Kim KH, et al
    The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
    Gynecol Oncol. 2024;189:64-67.
    PubMed     Abstract available


  288. KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
    Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
    Gynecol Oncol. 2024;189:68-74.
    PubMed     Abstract available


  289. CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
    Molecular classification improves preoperative risk assessment of endometrial cancer.
    Gynecol Oncol. 2024;189:56-63.
    PubMed     Abstract available


  290. BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
    Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
    Gynecol Oncol. 2024;189:49-55.
    PubMed     Abstract available


  291. SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
    Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
    Gynecol Oncol. 2024;189:41-48.
    PubMed     Abstract available


  292. POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
    Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
    Gynecol Oncol. 2024;189:37-40.
    PubMed     Abstract available


  293. ANDRES S, Finch L, Iasonos A, Zhou Q, et al
    Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
    Gynecol Oncol. 2024;189:30-36.
    PubMed     Abstract available


  294. MAHONEY DE, Mukherjee R, Thompson J
    Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
    Gynecol Oncol. 2024;189:24-29.
    PubMed     Abstract available


  295. MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
    Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
    Gynecol Oncol. 2024;189:16-23.
    PubMed     Abstract available


  296. ARO K, Pasanen A, Butzow R, Loukovaara M, et al
    The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Gynecol Oncol. 2024;189:9-15.
    PubMed     Abstract available


  297. GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
    A toolkit for a modern gynecologic oncology tissue bank.
    Gynecol Oncol. 2024;189:1-8.
    PubMed     Abstract available


  298. EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
    Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
    Gynecol Oncol. 2024;188:169-183.
    PubMed     Abstract available


  299. KUMAR PP, Smith D, Key J, Dong H, et al
    Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
    Gynecol Oncol. 2024;188:162-168.
    PubMed     Abstract available


  300. SHALOWITZ DI, Rajczi A
    Refining research on access to gynecologic cancer care: The DIMeS framework.
    Gynecol Oncol. 2024;188:158-161.
    PubMed     Abstract available


  301. CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
    Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
    Gynecol Oncol. 2024;188:147-157.
    PubMed     Abstract available


  302. NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
    Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
    Gynecol Oncol. 2024;188:140-146.
    PubMed     Abstract available


  303. STEWART KT, Jafari H, Pattillo J, Santos J, et al
    Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
    Gynecol Oncol. 2024;188:131-139.
    PubMed     Abstract available


  304. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
    The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2024;186:110-116.
    PubMed     Abstract available


    June 2024
  305. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
    Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
    Gynecol Oncol. 2024;188:97-102.
    PubMed     Abstract available


  306. MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
    Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
    Gynecol Oncol. 2024;188:111-119.
    PubMed     Abstract available


  307. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
    NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
    Gynecol Oncol. 2024;188:103-110.
    PubMed     Abstract available


  308. KA K, Cordoba A, Cagetti LV, Schiappa R, et al
    Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
    Gynecol Oncol. 2024;188:90-96.
    PubMed     Abstract available


  309. KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
    Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
    Gynecol Oncol. 2024;188:83-89.
    PubMed     Abstract available


  310. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
    Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Gynecol Oncol. 2024;188:52-57.
    PubMed     Abstract available


  311. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
    Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
    Gynecol Oncol. 2024;188:60-70.
    PubMed     Abstract available


  312. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
    Gynecol Oncol. 2024;188:58-59.
    PubMed    


  313. BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
    The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
    Gynecol Oncol. 2024;188:44-51.
    PubMed     Abstract available


  314. GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
    Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
    Gynecol Oncol. 2024;188:35-43.
    PubMed     Abstract available


  315. CHEN H, Chen Y, Zheng A, Tan X, et al
    Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
    Gynecol Oncol. 2024;188:27-34.
    PubMed     Abstract available


  316. WALKER CA, Edwards C, McIntire D, Makepeace L, et al
    Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
    Gynecol Oncol. 2024;188:22-26.
    PubMed     Abstract available


  317. PATEL KB, Escamilla V, Wolfe L, Morris T, et al
    Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
    Gynecol Oncol. 2024;188:8-12.
    PubMed     Abstract available


  318. FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
    Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
    Gynecol Oncol. 2024;186:211-215.
    PubMed     Abstract available


  319. BORHO L, Bao R, Elishaev E, Dinkins KD, et al
    Association of allostatic load with overall survival in epithelial ovarian cancer.
    Gynecol Oncol. 2024;186:204-210.
    PubMed     Abstract available


  320. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
    Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
    Gynecol Oncol. 2024;187:249-252.
    PubMed    


  321. MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
    Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
    PubMed     Abstract available


  322. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
    Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
    Gynecol Oncol. 2024;187:241-248.
    PubMed     Abstract available


  323. VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
    Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;187:128-138.
    PubMed     Abstract available


  324. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
    Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
    Gynecol Oncol. 2024;186:199-203.
    PubMed     Abstract available


  325. BERTON D, Pautier P, Lorusso D, Gennigens C, et al
    Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
    Gynecol Oncol. 2024;186:191-198.
    PubMed     Abstract available


  326. CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
    Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
    Gynecol Oncol. 2024;185:165-172.
    PubMed     Abstract available


  327. SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
    A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
    Gynecol Oncol. 2024;185:83-94.
    PubMed     Abstract available


  328. FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
    Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
    Gynecol Oncol. 2024;185:58-67.
    PubMed     Abstract available


  329. HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
    High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
    Gynecol Oncol. 2024;185:17-24.
    PubMed     Abstract available


    May 2024
  330. FRANCO S, Godley LA
    Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
    Gynecol Oncol. 2024;187:235-240.
    PubMed     Abstract available


  331. LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
    Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
    Gynecol Oncol. 2024;187:227-234.
    PubMed     Abstract available


  332. PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
    Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Gynecol Oncol. 2024;187:221-226.
    PubMed     Abstract available


  333. YUAN G, Zhang K, Zheng H, Wu Y, et al
    Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
    Gynecol Oncol. 2024;187:212-220.
    PubMed     Abstract available


  334. CARBALLO EV, Kim KH, Penn CA
    Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;187:204-211.
    PubMed     Abstract available


  335. OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
    ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
    Gynecol Oncol. 2024;187:184-191.
    PubMed     Abstract available


  336. PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
    A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
    Gynecol Oncol. 2024;187:178-183.
    PubMed     Abstract available


  337. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
    Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
    Gynecol Oncol. 2024;187:170-177.
    PubMed     Abstract available


  338. LARAJA A, Connor Y, Poulson MR
    The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
    Gynecol Oncol. 2024;187:163-169.
    PubMed     Abstract available


  339. FERRIS JS, Prest MT, Hur C, Chen L, et al
    Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
    Gynecol Oncol. 2024;187:151-162.
    PubMed     Abstract available


  340. ZENATRI M, Perennec T, Michon C, Gernier F, et al
    Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
    Gynecol Oncol. 2024;187:139-144.
    PubMed     Abstract available


  341. HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
    A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
    Gynecol Oncol. 2024;187:120-127.
    PubMed     Abstract available


  342. LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
    A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Gynecol Oncol. 2024;187:105-112.
    PubMed     Abstract available


  343. ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
    Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
    Gynecol Oncol. 2024;187:98-104.
    PubMed     Abstract available


  344. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
    Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Gynecol Oncol. 2024;187:92-97.
    PubMed     Abstract available


  345. KIM JH, Han KH, Park EY, Kim ET, et al
    Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;187:85-91.
    PubMed     Abstract available


  346. FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
    Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;187:80-84.
    PubMed     Abstract available


  347. LIANG S, Ge H, Zhou S, Tang J, et al
    Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
    Gynecol Oncol. 2024;187:64-73.
    PubMed     Abstract available


  348. CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
    Trop-2 expression and the tumor immune microenvironment in cervical cancer.
    Gynecol Oncol. 2024;187:51-57.
    PubMed     Abstract available


  349. GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    Gynecol Oncol. 2024;186:182-190.
    PubMed     Abstract available


  350. MATSUO K, Chen L, Klar M, Lee MW, et al
    Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
    Gynecol Oncol. 2024;187:37-45.
    PubMed     Abstract available


  351. MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
    Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
    Gynecol Oncol. 2024;187:30-36.
    PubMed     Abstract available


  352. PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
    Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
    Gynecol Oncol. 2024;187:21-29.
    PubMed     Abstract available


  353. DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
    Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
    Gynecol Oncol. 2024;187:12-20.
    PubMed     Abstract available


  354. RING KL, Duska LR
    How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
    Gynecol Oncol. 2024;184:8-15.
    PubMed     Abstract available


  355. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
    Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
    Gynecol Oncol. 2024;184:16-23.
    PubMed     Abstract available


    April 2024
  356. HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
    Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
    Gynecol Oncol. 2024;186:176-181.
    PubMed     Abstract available


  357. JIANG Z, Zhu M, Zhang L, Cui H, et al
    Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
    Gynecol Oncol. 2024;187:1-11.
    PubMed     Abstract available


  358. HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
    Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
    Gynecol Oncol. 2024;184:254-258.
    PubMed     Abstract available


  359. SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
    "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
    Gynecol Oncol. 2024;186:170-175.
    PubMed     Abstract available


  360. CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
    Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Gynecol Oncol. 2024;186:161-169.
    PubMed     Abstract available


  361. PENG H, Jiang J, Li L, Hao Z, et al
    Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
    Gynecol Oncol. 2024;186:154-160.
    PubMed     Abstract available


  362. ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
    Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Gynecol Oncol. 2024;186:144-153.
    PubMed     Abstract available


  363. PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
    ChatGPT accurately performs genetic counseling for gynecologic cancers.
    Gynecol Oncol. 2024;183:115-119.
    PubMed     Abstract available


  364. WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
    The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
    Gynecol Oncol. 2024;186:137-143.
    PubMed     Abstract available


  365. ZHAO Z, Wang J, Kong W, Fang Z, et al
    Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
    Gynecol Oncol. 2024;186:126-136.
    PubMed     Abstract available


  366. NELSON AT, Harris AK, Watson D, Kamihara J, et al
    Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
    Gynecol Oncol. 2024;186:117-125.
    PubMed     Abstract available


  367. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;186:104-109.
    PubMed     Abstract available


  368. ESPINOSA I, D'Angelo E, Prat J
    Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Gynecol Oncol. 2024;186:94-103.
    PubMed     Abstract available


  369. MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
    Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
    Gynecol Oncol. 2024;186:85-93.
    PubMed     Abstract available


  370. GITTO SB, Ihewulezi CJN, Powell DJ Jr
    Adoptive T cell therapy for ovarian cancer.
    Gynecol Oncol. 2024;186:77-84.
    PubMed     Abstract available


  371. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
    Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2024;186:69-76.
    PubMed     Abstract available


  372. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
    Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
    Gynecol Oncol. 2024;186:61-68.
    PubMed     Abstract available


  373. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
    Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
    Gynecol Oncol. 2024;186:53-60.
    PubMed     Abstract available


  374. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
    Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
    Gynecol Oncol. 2024;183:103-114.
    PubMed     Abstract available


  375. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
    High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:42-52.
    PubMed     Abstract available


  376. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
    Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
    Gynecol Oncol. 2024;186:35-41.
    PubMed     Abstract available



  377. Introduction to SGO VSI.
    Gynecol Oncol. 2024;183:A7.
    PubMed    


  378. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
    Gynecol Oncol. 2024;183:R1.
    PubMed    


    March 2024
  379. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:26-34.
    PubMed     Abstract available


  380. SHEN X, Wang J, Deng B, Chen S, et al
    High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
    Gynecol Oncol. 2024;183:93-102.
    PubMed     Abstract available


  381. SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
    Delayed publication of clinical trials in gynecologic oncology.
    Gynecol Oncol. 2024;183:74-77.
    PubMed     Abstract available


  382. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
    Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
    Gynecol Oncol. 2024;186:9-16.
    PubMed     Abstract available


  383. DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
    Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
    Gynecol Oncol. 2024;186:1-8.
    PubMed     Abstract available


  384. WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
    System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
    Gynecol Oncol. 2024;183:85-92.
    PubMed     Abstract available


  385. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2024;183:78-84.
    PubMed     Abstract available


  386. KIM NK, Choi CH, Seong SJ, Lee JM, et al
    Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
    Gynecol Oncol. 2024;183:68-73.
    PubMed     Abstract available


  387. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
    Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
    Gynecol Oncol. 2024;183:61-67.
    PubMed     Abstract available


  388. LIANG MI, Dholakia JD, Lee GM, Wang L, et al
    Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
    Gynecol Oncol. 2024;183:53-60.
    PubMed     Abstract available


  389. AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
    Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
    Gynecol Oncol. 2024;183:47-52.
    PubMed     Abstract available


  390. HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
    Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2024;183:39-46.
    PubMed     Abstract available


  391. LEVINE BJ
    Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
    PubMed    


  392. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
    Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
    Gynecol Oncol. 2024;183:33-38.
    PubMed     Abstract available


  393. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
    Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
    Gynecol Oncol. 2024;183:15-24.
    PubMed     Abstract available


  394. BYRNE M, Sia TY, Fong C, Khurram A, et al
    Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
    Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
    PubMed     Abstract available


  395. GASS P, Thiel FC, Haberle L, Ackermann S, et al
    Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gynecol Oncol. 2024;183:25-32.
    PubMed     Abstract available


  396. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
    Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
    Gynecol Oncol. 2024;183:7-8.
    PubMed    


  397. GLASER GE, Maddy B, Kumar A, Ishitani K, et al
    Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
    Gynecol Oncol. 2024;183:9-14.
    PubMed     Abstract available


  398. PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
    Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
    Gynecol Oncol. 2024;185:194-201.
    PubMed     Abstract available


  399. GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
    2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
    Gynecol Oncol. 2024;184:245-253.
    PubMed     Abstract available


  400. RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
    Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;185:186-193.
    PubMed     Abstract available


  401. NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
    Real world challenges and disparities in the systemic treatment of ovarian cancer.
    Gynecol Oncol. 2024;185:180-185.
    PubMed     Abstract available


  402. OLAWAIYE AB
    2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
    Gynecol Oncol. 2024;184:243-244.
    PubMed    


  403. EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
    Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
    Gynecol Oncol. 2024;185:173-179.
    PubMed     Abstract available


  404. GLASER GE, Dowdy SC
    Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
    Gynecol Oncol. 2024;182:A1-A2.
    PubMed    


  405. CHEN W, Xie J, Gao C, Zhang C, et al
    Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2024;182:108-114.
    PubMed     Abstract available


    February 2024
  406. CAO B, Li Y, Liu Y, Chen X, et al
    A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
    Gynecol Oncol. 2024;185:156-164.
    PubMed     Abstract available


  407. CHEN Y, Yang J, Wan Y, Li Q, et al
    DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
    Gynecol Oncol. 2024;185:148-155.
    PubMed     Abstract available


  408. COSTALES AB, Crane EK, Chambers L, Yao M, et al
    Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
    Gynecol Oncol. 2024;185:143-147.
    PubMed     Abstract available


  409. SALMAN L, Covens A, Vicus D, Podolsky S, et al
    The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
    Gynecol Oncol. 2024;185:138-142.
    PubMed     Abstract available


  410. RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
    Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Gynecol Oncol. 2024;185:128-137.
    PubMed     Abstract available


  411. AGUSTI N, Kanbergs A, Nitecki R
    Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
    Gynecol Oncol. 2024;185:121-127.
    PubMed     Abstract available


  412. MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
    Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
    PubMed     Abstract available


  413. APPLEBAUM AJ
    The importance of family-focused care in the setting of advanced gynecological cancers.
    Gynecol Oncol. 2024;181:A1-A2.
    PubMed    


  414. PELTECU G
    Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
    Gynecol Oncol. 2024;181:40-45.
    PubMed     Abstract available


  415. VASTA FM, Cormio G, Cassani C, Bergamini A, et al
    Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
    Gynecol Oncol. 2024;181:28-32.
    PubMed     Abstract available


  416. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
    Gynecol Oncol. 2024;181:186.
    PubMed    


    January 2024
  417. FADER AN, Ko EM, Pollock BD, Blank SV, et al
    An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
    Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
    PubMed     Abstract available


    October 2023
  418. KIM JH, Kim SI, Park EY, Ha HI, et al
    Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;179:24-32.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.